Index by author

Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8⁺ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8⁺ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

Although cytokines modulate immune responses, systemic administration necessitates high doses. With the use of cytokines fused to "VHHs" specific for PD-L1, systemic delivery of low doses led to intratumoral localization, allowing for therapeutic effects in pancreatic cancer models.

Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

Natural killer cells can carry chimeric antigen receptors (CARs). CARs were expressed in NK cells by transient transfection of mRNA. Functional responses of CAR-expressing NK cells depended on their diversification as well as donor and recipient HLA genotypes.

Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

Tumoricidal T-cell receptors (TCRs) are key components of some immunotherapies. TCR analysis of single T cells isolated from tumor-infiltrating lymphocytes identified TCRs with killing activity in vivo and in vitro, without prior knowledge of their peptide-MHC specificity.

Certain cancer immunotherapies use transferred γδ T cells. LDL-cholesterol inhibited activation and antitumor function of human γδ T cells in models of breast cancer. Management of LDL-cholesterol levels may improve results from immunotherapies based on γδ T cells.

Stromal and immune cells are required for effective responses to intratumoral cyclic dinucleotide therapy. Responses leading to productive innate and adaptive antitumor responses are demonstrated and highlight the cooperation between the tumor stroma and immune compartments during immunotherapy.

Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio.

The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8⁺ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.

mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

mRCC patients who had a clinical response to PD-1/PD-L1 blockade and discontinued treatment due to irAE continued to derive prolonged clinical benefit after treatment was stopped. Current clinical trials are exploring customized approaches to application of PD-1/PD-L1 blockade.

The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8⁺ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

Mice with an NK cell–specific knockout of CDK8 were used to show that loss of CDK8 enhances NK-cell cytotoxicity and tumor surveillance in vivo. Thus, CDK8 is a promising target for immunotherapy against cancer.

The kinase inhibitor imatinib is used to treat gastrointestinal stromal tumors. Combined with agonistic anti-CD40, macrophages and CD8⁺ T cells improved the antitumor effects of imatinib alone, supporting the combination's use in patients with these tumors.

Progression of human colorectal cancer coincides with a downregulated IFNγ gene signature. IL-33 signaling induced this IFNγ–signature in mesenchymal cells of the mouse colon and suppressed tumor formation. Therapeutically, IL-33 administration restricted colon cancer growth in mice.